News-CDMO Pharmaceutical

CPHI Milan 2026 will take place from 6–8 October 2026 at Fiera Milano, Italy. As a major international platform for the pharmaceutical industry, CPHI brings together suppliers, innovators and professionals from across the global pharmaceutical value chain, facilitating industry exchange, technological innovation, supply-chain collaboration and international business development. According to official figures for the 2025 edition, the event welcomed approximately 62,000 attendees and more than 2,900 exhibiting companies, with representation from over 166 countries, demonstrating its extensive global reach and industry influence.

CPHI Milan 2026 will cover key sectors across the pharmaceutical supply chain, including APIs, bioproduction, contract services, CRO, excipients, fine chemicals, finished dosage forms, pharmaceutical machinery and equipment, and packaging and drug delivery. New zones for 2026 will further focus on AI & Tech, Cold Chain & Logistics, Contamination Control and Labelling. The conference programme will feature more than 250 expert speakers addressing topics such as AI and technology, biomanufacturing, R&D, manufacturing, supply chains, regulation and policy, packaging and drug delivery, and sustainability. Through exhibitions, expert-led content and business networking, CPHI Milan 2026 provides a key platform for pharmaceutical companies to explore emerging industry trends, connect with global resources and partners, and identify new opportunities for innovation and international collaboration.

About Zhejiang CDMO Pharmaceutical

Zhejiang CDMO Pharmaceutical is a platform-based enterprise specializing in CDMO/CMO services and is a wholly-owned subsidiary of Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (Stock Code: 301096.SZ). The company focuses on Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and technology transfer and commercial manufacturing, providing clients with integrated services covering technology R&D, process scale-up, product transformation, process validation, quality studies, regulatory submissions, and commercial production.

Zhejiang CDMO Pharmaceutical operates approximately 140,000 m² of GMP-standard manufacturing facilities and laboratories, with more than 100 API and formulation production lines covering 25 dosage forms, including oral solids, oral liquids, injections, ophthalmic products, inhalation solutions, topical formulations and APIs. As of April 2026, Zhejiang CDMO Pharmaceutical had collaborated with 232 pharmaceutical companies and completed 619 validation projects, including 516 formulation projects and 103 API projects. A total of 263 formulation projects have been approved, 50 API products have obtained active registration status, while 130 formulation projects and 32 API projects have entered commercial production. In addition, three APIs have been submitted for EU registration, with three CEPs obtained.

With integrated capabilities from API to FDF, technology transfer to scale-up, and regulatory filing to commercialization, Zhejiang CDMO Pharmaceutical is committed to providing efficient and reliable CDMO/CMO solutions for global pharmaceutical partners and accelerating the journey from development to market.

next chapter:Good News on Centralized Procurement | Bio-Sincerity Pharma-Tech's wholly-owned subsidiary Zhejiang CDMO Pharmaceutical has 5 products selected for the 12th batch of National Drug Centralized Procurement!

Go Back

You are welcome to contact us via the online form below.

We will answer your inquiries in various ways, and jointly provide customized professional consultation and solutions for your research and development needs.

What information and information do you want to know?